Evidence map›Paper›PMID 42223334›Full record

ArticleEuropean journal of neurology2026

Distinct UNC13A Haplotype Blocks Define Disease Severity and Survival in Chinese Amyotrophic Lateral Sclerosis.

Cailin He, Ziqin Liu, Yanchun Yuan, Linxin Tang, Meirong Wang, Yongchao Li, Qianqian Zhao, Ling Weng, Juan Du, Hanjun Wu and 6 more

Abstract read
In one paragraph

Article in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Cailin HeDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.
Ziqin LiuDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.
Yanchun YuanDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.
Linxin TangDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.ORCID https://orcid.org/0000-0002-9058-8340
Meirong WangDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.
Yongchao LiDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.
Qianqian ZhaoDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.
Ling WengDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.
Juan DuDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.
Hanjun WuDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.
Fan HuDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.
Renshi XuDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.ORCID https://orcid.org/0000-0003-0313-3434
Jifeng GuoDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.ORCID https://orcid.org/0000-0002-3658-3928
Lu ShenDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.ORCID https://orcid.org/0000-0002-3393-8578
Beisha TangDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.ORCID https://orcid.org/0000-0003-2120-1576
Junling WangDepartment of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, P. R. China.ORCID https://orcid.org/0000-0001-5117-5204

Funding

National Science and Technology Innovation 2030 Major Program STI2030‑MajorProjects2021ZD0201803the Ganpo Outstanding Talents Support Program-Cultivation Project for Academic and Technical Leaders in Key Disciplines 20243BCE51002the Ganpo Talents Program-Innovation Leading Talent Project (Medical and Health Care Category) gpyc20240194the Jiangxi Provincial Health Technology Project 202510014the Jiangxi Provincial Natural Science Foundation 20242BAB26135the National Key R&D Program of China 2021YFA0805202the National Natural Science Foundation of China 82171431the National Natural Science Foundation of China 82371445
6 · The paper itself

Abstract

backgroundUNC13A is a genetic modifier of amyotrophic lateral sclerosis (ALS) in European populations, but its role in Chinese patients remains incompletely characterized. We investigated the spectrum of UNC13A variation and its impact on disease risk and progression in a Chinese ALS cohort.

methodsWe performed an integrated genetic analysis of 1,533 Chinese ALS patients and 1,405 controls, including rare variant burden testing, genome-wide survival analysis, haplotype mapping, and conditional analyses. An integrated clinical-genetic prognostic score was developed and validated.

resultsRare deleterious UNC13A variants were not associated with ALS risk. We identified two independent haplotype blocks with distinct clinical impacts. Block 1 (tagged by rs75421007) was associated with reduced baseline muscle strength (p = 0.030), while Block 2 (tagged by rs78549703), a brain-specific splicing QTL, was the primary driver of survival heterogeneity. The European variant rs12608932 showed a survival association in single-marker analysis (p = 0.024), but conditional analyses revealed its effect was not independent of Block 2. An integrated prognostic score combining clinical factors and Block 2 haplotype stratified patients into low-, intermediate-, and high-risk groups (median survival: 52.6, 37.1, and 32.0 months; p < 0.001), with decision curve analysis confirming clinical utility.

conclusionsThis study delineates UNC13A genetic architecture in Chinese ALS, identifying two independent haplotype blocks that differentially influence disease severity and survival. The Block 2 haplotype, which includes a brain sQTL, is a major determinant of survival heterogeneity and may inform patient stratification in future studies.

Indexed as

Amyotrophic Lateral SclerosisNerve Tissue ProteinsAdultAgedEast Asian PeopleFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHaplotypesHumansMaleMiddle AgedPolymorphism, Single NucleotideSeverity of Illness IndexNerve Tissue ProteinsUNC13B protein, humanamyotrophic lateral sclerosisChinese populationgenetic modifierhaplotypeprognostic modelUNC13A

Identifiers

PMID42223334
PMCPMC13239109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.